Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis

Published on Jul 23, 2021in British Journal of Surgery5.676
· DOI :10.1093/BJS/ZNAA141
Claudio Ricci28
Estimated H-index: 28
(UNIBO: University of Bologna),
Stefano Partelli43
Estimated H-index: 43
(UniSR: Vita-Salute San Raffaele University)
+ 14 AuthorsRiccardo Casadei31
Estimated H-index: 31
(UNIBO: University of Bologna)
BACKGROUND Outcomes after surgery for sporadic pancreatic neuroendocrine neoplasms (Pan-NENs) were evaluated. METHODS This multicentre study included patients who underwent radical pancreatic resection for sporadic non-functioning Pan-NENs. In survival analysis, the risk of mortality in this cohort was analysed in relation to that of the matched healthy Italian population. Relative survival (RS) was calculated as the rate between observed and expected survival. Factors related to RS were investigated using multivariable modelling. RESULTS Among 964 patients who had pancreatic resection for sporadic non-functioning Pan-NENs, the overall RS rate was 91.8 (95 per cent c.i. 81.5 to 96.5) per cent. 2019 WHO grade (hazard ratio (HR) 5.75 (s.e. 4.63); P = 0.030) and European Neuroendocrine Tumour Society (ENETS) TNM stage (6.73 (3.61); P < 0.001) were independent predictors of RS. The probability of a normal lifespan for patients with G1, G2, G3 Pan-NENS, and pancreatic neuroendocrine carcinomas (Pan-NECs) was 96.7, 54.8, 0, and 0 per cent respectively. The probability of a normal lifespan was 99.8, 99.3, 79.8, and 46.8 per cent for those with stage I, II, III, and IV disease respectively. The overall disease-free RS rate was 73.6 (65.2 to 79.5) per cent. 2019 WHO grade (HR 2.10 (0.19); P < 0.001) and ENETS TNM stage (HR 2.50 (0.24); P < 0.001) significantly influenced disease-free RS. The probability of disease-free survival was 93.2, 84.9, 45.2, and 6.8 per cent for patients with stage I, II, III, and IV disease, and 91.9, 45.2, 9.4, and 0.7 per cent for those with G1, G2, G3 Pan-NENS, and Pan-NECs, respectively. CONCLUSION A surgical approach seems without benefit for Pan-NECs, and unnecessary for small G1 sporadic Pan-NENs. Surgery alone may be insufficient for stage III-IV and G3 Pan-NENs.
📖 Papers frequently viewed together
97 Citations
2 Citations
1 Citations
#1Elettra Merola (FAU: University of Erlangen-Nuremberg)H-Index: 9
#2Anja RinkeH-Index: 22
Last. Marianne Pavel (Charité)H-Index: 52
view all 20 authors...
Background While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these patients, as well as the use of adjuvant chemotherapy, are still controversial. The aim of the present work is to describe, in a retrospective series of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) G3, the overall survival (OS) rate and...
15 CitationsSource
#1Claudio Ricci (UNIBO: University of Bologna)H-Index: 28
#2Stefano Partelli (UniSR: Vita-Salute San Raffaele University)H-Index: 43
Last. Massimo Falconi (UniSR: Vita-Salute San Raffaele University)H-Index: 105
view all 10 authors...
Overall survival (OS) is considered as the standard measure of outcome in oncology. However, considering that resectable pancreatic neuroendocrine neoplasms (Pan-NENs) usually have a long OS, the feasibility of prospective studies is questionable due to a long follow-up period needed. The primary endpoint was to validate the use of disease-free survival (DFS) as a surrogate measure of OS. The secondary endpoint was to calculate the gain in sample size using DFS instead of OS in hypothetical pros...
1 CitationsSource
#1Lode K. J. VandammeH-Index: 23
Last. Ignace H.J.T. de HinghH-Index: 43
view all 4 authors...
Survival functions are often characterized by a median survival time or a 5-year survival. Whether or not such representation is sufficient depends on tumour development. Different tumour stages have different mean survival times after therapy. The validity of an exponential decay and the origins of deviations are substantiated. The paper shows, that representation of survival data as logarithmic functions visualizes differences better, which allows for differentiating short- and long-term dynam...
4 CitationsSource
#1Stefano PartelliH-Index: 43
#2Michele MazzaH-Index: 4
Last. Massimo FalconiH-Index: 105
view all 7 authors...
Abstract Background International guidelines suggest a watchful strategy for small nonfunctioning pancreatic neuroendocrine tumors. The aim of this study was to evaluate the management and indications for surgery in patients with asymptomatic nonfunctioning pancreatic neuroendocrine tumors ≤2 cm. Methods Patients with asymptomatic, incidental, sporadic nonfunctioning pancreatic neuroendocrine tumors ≤2 cm without nodal or distant metastases were included (2012–2016). A comparison between active ...
19 CitationsSource
#1Guido Rindi (UCSC: Catholic University of the Sacred Heart)H-Index: 87
#2Catherine KlersyH-Index: 102
Last. Massimo Falconi (UniSR: Vita-Salute San Raffaele University)H-Index: 105
view all 47 authors...
Background: The World Health Organization (WHO) and the American Joint Cancer Committee (AJCC) modified the grading of pancreatic neuroendocrine neoplasms from a three-tier (WHO-AJCC 2010) to a four-tier system by introducing the novel category of NET G3 (WHO-AJCC 2017). Objectives: This study aims at validating the WHO-AJCC 2017 and identifying the most effective grading system. Method: A total of 2,102 patients were enrolled; entry criteria were: (i) patient underwent surgery; (ii) at least 2 ...
39 CitationsSource
#1Luca Landoni (University of Verona)H-Index: 19
#2Giovanni Marchegiani (University of Verona)H-Index: 29
Last. Claudio BassiH-Index: 110
view all 26 authors...
OBJECTIVE: The objective of the present analysis is 2-fold: first, to define the evolution of time trends on the surgical approach to pancreatic neuroendocrine neoplasms (Pan-NENs); second, to perform a complete analysis of the predictors of oncologic outcome. BACKGROUND: Reflecting their rarity and heterogeneity, Pan-NENs represent a clinical dilemma. In particular, there is a scarcity of data regarding their long-term follow-up after surgical resection. METHODS: From the Institutional Pan-NEN ...
27 CitationsSource
#1Arvind Dasari (University of Texas MD Anderson Cancer Center)H-Index: 24
#2Chan Shen (University of Texas MD Anderson Cancer Center)H-Index: 17
Last. James C. Yao (University of Texas MD Anderson Cancer Center)H-Index: 74
view all 8 authors...
Importance The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, but updated epidemiologic data are lacking. Objective To explore the evolving epidemiology and investigate the effect of therapeutic advances on survival of patients with NETs. Design, Setting, and Participants A retrospective, population-based study using nationally representative data from the Surveillance, Epidemiology, and End Results (SEER) program was conducted to evaluate 64 971 patients with...
1,056 CitationsSource
#1Claudio Ricci (UNIBO: University of Bologna)H-Index: 28
#2Giovanni Taffurelli (UNIBO: University of Bologna)H-Index: 15
Last. Riccardo Casadei (UNIBO: University of Bologna)H-Index: 31
view all 10 authors...
Abstract Backgound There is currently there is substantial controversy regarding the best management of non-functioning pancreatic neuroendocrine tumours ≤2 cm. Methods Retrospective study involving 102 surgically treated patients affected by non-functioning pancreatic neuroendocrine tumours. Patients having small tumours (≤2 cm) (Group A) and those having large tumours (>2 cm) (Group B) were compared regarding demographics, clinical and pathological factors with the aim of evaluating the risk o...
11 CitationsSource
Objective:The aim of this study was to predict recurrence in patients with grade 1 or 2 nonfunctioning pancreatic neuroendocrine tumors (NF-pNET) after curative resection.Background:Surgical resection is the preferred treatment for NF-pNET; however, recurrence occurs frequently after curative surger
67 CitationsSource
#1Stefano CrippaH-Index: 60
#2Stefano PartelliH-Index: 43
Last. Massimo FalconiH-Index: 105
view all 10 authors...
Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology
21 CitationsSource
Cited By1
Abstract Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare tumors that have been increasingly recognized in recent years. They are highly heterogeneous and exhibit a diverse clinical course, along with a variable metastatic propensity related to their molecular biology profile, grade, extent of disease and functional status. PNENs are divided into functioning and non-functioning tumor forms. Their pathological classification is based mainly on their histology and proliferative acti...